⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Immedica Pharma AB and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Immedica Pharma AB
↗Stockholm, Sweden
Immedica is a specialized pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization and distribution of medicines for rare diseases and specialty care. The company operates across Europe, the Middle East, and the United States, providing a platform for niche therapies with high unmet medical needs.
Since its founding in 2018, Immedica has built a robust portfolio and pipeline through strategic in-licensing, acquisitions, and organic growth. The company is backed by investment firms KKR and Impilo, supporting its mission to deliver innovative treatments to patients in over 50 countries.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Rare Disease Therapeutics
SIZE & FINANCIALS
Employees:101-200
Revenue:$100M+
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Private Equity Backed
Investors:KKR, Impilo
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Enzyme replacement therapy
Active Trials:27
Trial Phases:-
FDA Approvals:0
EMA Approvals:5
CORPORATE STRUCTURE
Subsidiaries:Immedica Pharma US Inc., Immedica UK Ltd
Key Partnerships:KKR (Investor/Partner), Impilo (Investor/Partner)
COMPETITION
Position:Challenger
Competitors:BeiGene, Moderna, AmerisourceBergen
LEADERSHIP
Key Executives:
Anders Edvell - CEO
Carl Belmadani - Chief Commercial Officer
Simon Falk - CFO
LINKS
Website:immedica.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immedica Pharma AB. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.